--- title: "Rapport Therapeutics (RAPP) news: offering and convertible notes" url: "https://aibio.space/companies/rapport-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "RAPP offering and convertible notes news: Rapport Therapeutics launches stock offering and convertible notes due 2032. Rapport Therapeutics, Inc." --- RAPP Rapport Therapeutics, Inc. NASDAQ · United States # Rapport Therapeutics (RAPP) news RAPP offering and convertible notes news Financings · 2026-10-27 ## [Rapport Therapeutics launches stock offering and convertible notes due 2032](https://aibio.space/news/rapport-therapeutics-launches-stock-offering-convertible-notes-due/) Rapport Therapeutics filed preliminary terms on October 27, 2026 for a stock offering and convertible notes due 2032. Both deal sizes are blank in the filings, and the company's cash was about $395.0 million at September 30, a figure it calls preliminary. ## Latest Rapport Therapeutics news 1. 2025-09-08 Financings [Rapport Therapeutics prices $250 million stock offering at $26.00 a share](https://aibio.space/news/rapport-therapeutics-prices-250-million-stock-offering-26-00-share/) Rapport priced 9,615,385 shares at $26.00 the day after reporting Phase 2a epilepsy data for RAP-219, with net proceeds of about $234.7 million. The data came from 30 treated patients and were tested against fixed null rates, not a placebo group. ## Rapport Therapeutics at a glance - **Ticker**: RAPP - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $436.1 million ### Related companies - [Whitehawk Therapeutics](https://aibio.space/companies/whitehawk-therapeutics/) NASDAQ: WHWK - [Aura Biosciences](https://aibio.space/companies/aura-biosciences/) NASDAQ: AURA - [MAIA Biotechnology](https://aibio.space/companies/maia-biotechnology/) AMEX: MAIA - [AFFYMAX INC](https://aibio.space/companies/affymax/) OTC: AFFY - [Zentalis Pharmaceuticals](https://aibio.space/companies/zentalis-pharmaceuticals/) NASDAQ: ZNTL - [Jade Biosciences](https://aibio.space/companies/jade-biosciences/) NASDAQ: JBIO - [CorMedix](https://aibio.space/companies/cormedix/) NASDAQ: CRMD - [Heron Therapeutics](https://aibio.space/companies/heron-therapeutics/) NASDAQ: HRTX ### Also on NASDAQ - [NATURES SUNSHINE PRODUCTS INC](https://aibio.space/companies/natures-sunshine-products/) NATR - [MediWound](https://aibio.space/companies/mediwound/) MDWD - [Hyperfine](https://aibio.space/companies/hyperfine/) HYPR - [GRAIL](https://aibio.space/companies/grail/) GRAL - [GT Biopharma](https://aibio.space/companies/gt-biopharma/) GTBP - [Lunai Bioworks](https://aibio.space/companies/lunai-bioworks/) LNAI ## Rapport Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$94.8 million](https://www.sec.gov/Archives/edgar/data/2012593/000119312526099360/) | [$60.9 million](https://www.sec.gov/Archives/edgar/data/2012593/000119312526099360/) | | Net income (loss) | [-$111.5 million](https://www.sec.gov/Archives/edgar/data/2012593/000119312526099360/) | [-$78.3 million](https://www.sec.gov/Archives/edgar/data/2012593/000119312526099360/) | | Cash from operations | [-$87.5 million](https://www.sec.gov/Archives/edgar/data/2012593/000119312526099360/) | [-$64.8 million](https://www.sec.gov/Archives/edgar/data/2012593/000119312526099360/) | | Cash and equivalents | [$52.6 million](https://www.sec.gov/Archives/edgar/data/2012593/000119312526333862/) | [$56.8 million](https://www.sec.gov/Archives/edgar/data/2012593/000119312526099360/) | | Short-term investments | [$437.9 million](https://www.sec.gov/Archives/edgar/data/2012593/000119312526333862/) | [$248.5 million](https://www.sec.gov/Archives/edgar/data/2012593/000119312526099360/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $63.6 million, plus short-term investments of $372.5 million, $436.1 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Rapport Therapeutics Has Rapport Therapeutics raised money recently? Our latest story on this, dated Oct 27, 2026: "Rapport Therapeutics launches stock offering and convertible notes due 2032". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/rapport-therapeutics-launches-stock-offering-convertible-notes-due/). Has Rapport Therapeutics sold convertible notes? Our latest story on this, dated Oct 27, 2026: "Rapport Therapeutics launches stock offering and convertible notes due 2032". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/rapport-therapeutics-launches-stock-offering-convertible-notes-due/). What is the ticker symbol of Rapport Therapeutics? Rapport Therapeutics, Inc. trades under the ticker RAPP on NASDAQ. Where is Rapport Therapeutics listed? Rapport Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Rapport Therapeutics? The SEC Central Index Key (CIK) for Rapport Therapeutics, Inc. is 2012593. Its filings are on SEC EDGAR. How many shares does Rapport Therapeutics have outstanding? 47,978,286 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-05. Which country or territory is Rapport Therapeutics listed under? Our directory records Rapport Therapeutics, Inc. under United States. What does Rapport Therapeutics do? Our directory classifies Rapport Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Rapport Therapeutics? The ISIN recorded for Rapport Therapeutics, Inc. is US75383L1026. Does aibio.space cover Rapport Therapeutics? aibio.space lists Rapport Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Rapport Therapeutics incorporated? SEC records list its state or country of incorporation as DE. Is Rapport Therapeutics profitable? Rapport Therapeutics, Inc. reported a net loss of $111.5 million for the fiscal year ended Dec 31, 2025, and used $87.5 million of cash in operations, per its annual report to the SEC. How much does Rapport Therapeutics spend on research and development? $94.8 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Rapport Therapeutics have? $436.1 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Rapport Therapeutics (RAPP) stock news? Our latest story on Rapport Therapeutics, dated Oct 27, 2026: "Rapport Therapeutics launches stock offering and convertible notes due 2032". Rapport Therapeutics filed preliminary terms on October 27, 2026 for a stock offering and convertible notes due 2032. Both deal sizes are blank in the filings, and the company's cash was about $395.0 million at September 30, a figure it calls preliminary. [Source](https://aibio.space/news/rapport-therapeutics-launches-stock-offering-convertible-notes-due/). ## Investor discussion: Rapport Therapeutics Members talk about Rapport Therapeutics (RAPP). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Rapport Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-10-27 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/2012593/000119312526434371/d348288d424b5.htm) 2. 2026-03-10 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/2012593/000119312526099421/d46288ds3asr.htm) 3. 2026-01-07 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/2012593/000119312526005482/d87801d424b5.htm) 4. 2025-09-08 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/2012593/000119312525198453/d847769d424b5.htm) 5. 2025-07-01 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/2012593/000119312525153415/d89513ds3.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:RAPP on TradingView](https://www.tradingview.com/symbols/NASDAQ-RAPP/). ## SEC filings and registration - **SEC name**: Rapport Therapeutics, Inc. - **CIK**: 2012593 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: RAPP (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 99 HIGH STREET, BOSTON, MA, 02110 - **Phone**: 857-321-8020 - **Shares outstanding**: 47,978,286 as of 2026-08-03 (10-Q filed 2026-08-05) - **Former names**: Rapport Therapeutics, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/2012593/000119312526425647/d185134d8k.htm) filed 2026-10-20 - [10-Q](https://www.sec.gov/Archives/edgar/data/2012593/000119312526333862/rapp-20260630.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/2012593/000119312526333853/rapp-20260805.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/2012593/000119312526265841/rapp-20260610.htm) filed 2026-06-10 - [10-Q](https://www.sec.gov/Archives/edgar/data/2012593/000119312526210355/rapp-20260331.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/2012593/000119312526210324/rapp-20260507.htm) filed 2026-05-07 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/2012593/000119312526171828/d35380ddef14a.htm) filed 2026-04-23 - [8-K](https://www.sec.gov/Archives/edgar/data/2012593/000119312526167078/rapp-20260421.htm) filed 2026-04-21 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002012593), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Rapport Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RAPP, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Rapport Therapeutics, Inc. - **Ticker**: RAPP - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US75383L1026 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-RAPP/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/rapport-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Rapport Therapeutics (RAPP) news: offering and convertible notes", 2026-10-31, https://aibio.space/companies/rapport-therapeutics/